Ignite Creation Date:
2024-05-06 @ 6:02 PM
Last Modification Date:
2024-10-26 @ 2:40 PM
Study NCT ID:
NCT05525546
Status:
COMPLETED
Last Update Posted:
2023-09-21
First Post:
2022-08-30
Brief Title:
Salmonella Conjugates CVD 2000 Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
Phase 1 Randomized Placebo-Controlled Study to Compare the Safety Reactogenicity and Immunogenicity of a Full-Strength Formulation of Trivalent Salmonella S EnteritidisS TyphimuriumS Typhi Vi Conjugate Vaccine TSCV a Half-Strength Formulation of TSCV and a Dilutional Half-Strength Dose of TSCV Against Invasive Salmonella Disease Administered Parenterally to Healthy US Adults
Status:
COMPLETED
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randomized placebo-controlled interventional study The main purpose of this research is to test the safety and measure the immune response of the trivalent vaccine against invasive Salmonella disease The vaccine will be tested over a range of doses
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None